Abstract
Breast cancer is a heterogeneous disease with different intrinsic subtypes. The conventional treatment of surgical resection, chemotherapy, immunotherapy and radiotherapy has not shown significant improvement in the survival rate of breast cancer patients. The therapeutics used cause bystander toxicities deteriorating healthy tissues. The breakthroughs of nanotechnology have been a promising feat in selective targeting of tumor site thus increasing the therapeutic gain. By the application of nanoenabled carriers, nanomedicines ensure targeted delivery, stability, enhanced cellular uptake, biocompatibility and higher apoptotic efficacy. The present review focuses on breakthrough of nanoscale intervention in targeted drug delivery as novel class of therapeutics. Nanoenabled carriers like polymeric and metallic nanoparticles, dendrimers, quantum dots, liposomes, solid lipid nanoparticles, carbon nanotubes, drug-antibody conjugates and exosomes revolutionized the targeted therapeutic delivery approach. These nanoassemblies have shown additional effect of improving the solubility of drugs such as paclitaxel, reducing the dose and toxicity. The present review provides an insight on the different drug conjugates employed/investigated to curb breast cancer using nanocarrier mediated targeted drug delivery. However, identification of appropriate biomarkers to target, clearer insight of the biological processes, batch uniformity, reproducibility, nanomaterial toxicity and stabilities are the hurdles faced by nanodrugs. The potential of nano-therapeutics delivery necessitates the agglomerated efforts of research community to bridge the route of nanodrugs for scale-up, commercialization and clinical applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Afzal M, Ameeduzzafar, Alharbi KS, Alruwaili NK, Al-Abassi FA, Al-Malki AAL, Anwar F (2021) Nanomedicine in treatment of breast cancer—a challenge to conventional therapy. Sem Cancer Biol 69:279–292. https://doi.org/10.1016/j.semcancer.2019.12.016
Ahmadi-Kashani M, Dehghani H, Zarrabi A (2020) A biocompatible nanoplatform formed by MgAl-layered double hydroxide modified Mn(3)O(4)/N-graphene quantum dot conjugated-polyaniline for pH-triggered release of doxorubicin. Mater Sci Eng 114:111055. https://doi.org/10.1016/j.msec.2020.111055〹
Akram M, Hussain R (2017) Nanohydrogels: history, development, and applications in drug delivery. Nanocellulose Nanohydrogel Matrices. https://doi.org/10.1002/9783527803835.ch11
Alawdi SH, Eidi H, Safar MM, Abdel-Wahhab MA (2019) Loading amlodipine on diamond nanoparticles: a novel drug delivery system. Nanotechnol Sci Appl 12:47–53. https://doi.org/10.2147/NSA.S232517
Aleanizy FS, Alqahtani FY, Seto S, Al Khalil N, Aleshaiwi L, Alghamdi M, Alsarra I (2020) Trastuzumab targeted neratinib loaded poly-amidoamine dendrimer nanocapsules for breast cancer therapy. Int J Nanomed 15:5433–5443. https://doi.org/10.2147/IJN.S256898
Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8(5):1483–1507. https://doi.org/10.1007/s13346-018-0551-3
Almuqrin AH, Al-Otaibi JS, Mary YS, Mary YS, Thomas R (2020) Structural study of letrozole and metronidazole and formation of self-assembly with graphene and fullerene with the enhancement of physical, chemical and biological activities. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1790420
Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-borojeni AA, Sahebkar A, Eslami S (2017) The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther 24(5):189–193. https://doi.org/10.1038/cgt.2017.9
Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Translational Med 4(3):1–16. https://doi.org/10.1002/btm2.10143
Arachchige MC, Reshetnyak YK, Andreev OA (2015) Advanced targeted nanomedicine. J Biotechnol 202:88–97. https://doi.org/10.1016/j.jbiotec.2015.01.009
Asghari F, Khademi R, Ranjbar FE, Malekshahi ZV, Majidi RF (2019) Application of nanotechnology in targeting of cancer stem cells: a review. Int J Stem Cells 12(2):227–239. https://doi.org/10.15283/ijsc19006
Avitabile E, Bedognetti D, Ciofani G, Bianco A, Delogu LG (2018) How can nanotechnology help the fight against breast cancer? Nanoscale 10(25):11719–11731. https://doi.org/10.1039/c8nr02796j
Avramović N, Mandić B, Savić-Radojević A, Simić T (2020) Polymeric nanocarriers of drug delivery systems in cancer therapy. Pharmaceutics 12(4):1–17. https://doi.org/10.3390/pharmaceutics12040298
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Rugo HS (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529–1541. https://doi.org/10.1056/NEJMoa2028485
Bartusik-Aebisher D, Chrzanowski G, Bober Z, Aebisher D (2021) An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro. Biomed Pharmacother 133:111053. https://doi.org/10.1016/j.biopha.2020.111053
Bayat P, Pakravan P, Salouti M, Dolatabadi JEN (2021) Lysine decorated solid lipid nanoparticles of epirubicin for cancer targeting and therapy. Adv Pharm Bull 11(1):96–103. https://doi.org/10.34172/apb.2021.010
Behera P, Patro BK (2018) Population based cancer registry of India—the challenges and opportunities. Asian Pac J Cancer Prev 19(10):2885–2889. https://doi.org/10.22034/APJCP.2018.19.10.2885
Bhagwat GS, Athawale RB, Gude RP, Md S, Alhakamy NA, Fahmy UA, Kesharwani P (2020) Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy. Front Pharmacol 11:614290. https://doi.org/10.3389/fphar.2020.614290
Biancacci I, Sun Q, Möckel D, Gremse F, Rosenhain S, Kiessling F, Sofias AM (2020) Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. J Controlled Release 328:805–816. https://doi.org/10.1016/j.jconrel.2020.09.046
Boix-Montesinos P, Soriano-Teruel PM, Armiñán A, Orzáez M, Vicent MJ (2021) The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev 173:306–330. https://doi.org/10.1016/j.addr.2021.03.018
Brocato TA, Coker EN, Durfee PN, Lin YS, Townson J, Wyckoff EF, Wang Z (2018) Understanding the connection between nanoparticle uptake and cancer treatment efficacy using mathematical modeling. Sci Rep 8(1):1–8. https://doi.org/10.1038/s41598-018-25878-8
Bromma K, Bannister A, Kowalewski A, Cicon L, Chithrani DB (2020) Elucidating the fate of nanoparticles among key cell components of the tumor microenvironment for promoting cancer nanotechnology. Cancer Nanotechnol 11(1):1–16. https://doi.org/10.1186/s12645-020-00064-6
Burande AS, Viswanadh MK, Jha A, Mehata AK, Shaik A, Agrawal N, Muthu MS (2020) EGFR targeted paclitaxel and piperine co-loaded liposomes for the treatment of triple negative breast cancer. AAPS PharmSciTech 21(5):151. https://doi.org/10.1208/s12249-020-01671-7
Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, Madhunapantula SRV, Jain V (2021) Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids Surf B 199:111535. https://doi.org/10.1016/j.colsurfb.2020.111535
Chauhan S, Jain N, Nagaich U (2020) Nanodiamonds with powerful ability for drug delivery and biomedical applications: recent updates on in vivo study and patents. J Pharm Anal 10:1–12. https://doi.org/10.1016/j.jpha.2019.09.003
Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang Q-J, Mandal T, Kundu A (2020) Targeted delivery of doxorubicin liposomes for Her-2+ breast cancer treatment. AAPS PharmSciTech 21(6):202. https://doi.org/10.1208/s12249-020-01743-8
Cui X, Deng X, Liang Z, Lu J, Shao L, Wang X, Sheng W (2021) Multicomponent-assembled nanodiamond hybrids for targeted and imaging guided triple-negative breast cancer therapy via a ternary collaborative strategy. Biomater Sci. https://doi.org/10.1039/d1bm00283j
Dahiya S, Dahiya R, Hernández E (2021) Nanocarriers for anticancer drug targeting: recent trends and challenges. Crit Rev Ther Drug Carrier Syst 38:49–103. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021035650
Daly AA, Rolph R, Cutress RI, Copson ER (2021) A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer 13:241–257. https://doi.org/10.2147/BCTT.S268401
Darwish GH, Asselin J, Tran MV, Gupta R, Kim H, Boudreau D, Algar WR (2020) Fully self-assembled silica nanoparticle-semiconductor quantum dot supra-nanoparticles and Immunoconjugates for enhanced cellular imaging by microscopy and smartphone camera. ACS Appl Mater Interfaces 12(30):33530–33540. https://doi.org/10.1021/acsami.0c09553
Dasgupta I, Chatterjee A (2021) Recent advances in miRNA delivery systems. Methods Protocols 4(1):1–18. https://doi.org/10.3390/mps4010010
Debnath S (2021) Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. Front Nanotechnol. https://doi.org/10.3389/fnano.2021.644564
Dong L, Li W, Yu L, Sun L, Chen Y, Hong G (2020) Ultrasmall Ag(2)Te quantum dots with rapid clearance for amplified computed tomography imaging and augmented photonic tumor hyperthermia. ACS Appl Mater Interfaces 12(38):42558–42566. https://doi.org/10.1021/acsami.0c12948
Elhissi AMA, Ahmed W, Hassan IU, Dhanak VR, D’Emanuele A (2012) Carbon nanotubes in cancer therapy and drug delivery. J Drug Delivery 2012:837327. https://doi.org/10.1155/2012/837327
Esnaashari SS, Muhammadnejad S, Amanpour S, Amani A (2020) A combinational approach towards treatment of breast cancer: an analysis of noscapine-loaded polymeric nanoparticles and doxorubicin. AAPS PharmSciTech 21(5):166. https://doi.org/10.1208/s12249-020-01710-3
Farooq MA, Aquib M, Farooq A, Haleem Khan D, Joelle Maviah MB, Sied Filli M, Wang B (2019) Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Artif Cells Nanomed Biotechnol 47(1):1674–1692. https://doi.org/10.1080/21691401.2019.1604535
Franco MS et al (2021) Investigation of the antitumor activity and toxicity of cisplatin loaded pH-sensitive-pegylated liposomes in a triple negative breast cancer animal model. J Drug Deliv Sci Technol 62:102400. https://doi.org/10.1016/j.jddst.2021.102400
Fu B, Dang M, Tao J, Li Y, Tang Y (2020) Mesoporous platinum nanoparticle-based nanoplatforms for combined chemo-photothermal breast cancer therapy. J Colloid Interface Sci 570:197–204. https://doi.org/10.1016/j.jcis.2020.02.051
Gkionis L, Campbell RA, Aojula H, Harris LK, Tirella A (2020) Manufacturing drug co-loaded liposomal formulations targeting breast cancer: influence of preparative method on liposomes characteristics and in vitro toxicity. Int J Pharm 590:119926. https://doi.org/10.1016/j.ijpharm.2020.119926
Godoy-Ortiz A, Sanchez-Muñoz A, Chica Parrado MR, Álvarez M, Ribelles N, Rueda Dominguez A, Alba E (2019) Deciphering HER2 breast cancer disease: biological and clinical implications. Front Oncol 9:1124. https://doi.org/10.3389/fonc.2019.01124
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. https://doi.org/10.1200/JCO.2005.04.937
Gregoriou Y, Gregoriou G, Yilmaz V, Kapnisis K, Prokopi M, Anayiotos A, Andreou C (2021) Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics 5(1):113–124. https://doi.org/10.7150/ntno.51955
Haider M, Abdin SM, Kamal L, Orive G (2020) Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. https://doi.org/10.3390/pharmaceutics12030288
Han D-W, Zhou M, Kalangi SK, Lin J, Huang P, Younis MR, He G (2020) Recent advances on graphene quantum dots for bioimaging applications. Front Chem 1:424. https://doi.org/10.3389/fchem.2020.00424
Hapuarachchige S, Artemov D (2020) Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. Front Oncol 10:1–8. https://doi.org/10.3389/fonc.2020.01131
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38. https://doi.org/10.1016/j.addr.2016.04.025
Harris JC, Scully MA, Day ES (2019) Cancer cell membrane-coated nanoparticles for cancer management. Cancers 11(12):1836. https://doi.org/10.3390/cancers11121836
Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, Khan A (2018) Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol 16(1):1. https://doi.org/10.1186/s12957-017-1299-9
Hejmady S, Pradhan R, Alexander A, Agrawal M, Singhvi G, Gorain B, Dubey SK (2020) Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today 25:2227–2244. https://doi.org/10.1016/j.drudis.2020.09.031
Hussain A, Haque MW, Singh SK, Ahmed FJ (2016) Optimized permeation enhancer for topical delivery of 5-fluorouracil-loaded elastic liposome using Design Expert: part II. Drug Deliv 23(4):1242–1253. https://doi.org/10.3109/10717544.2015.1124473
Jaganathan H, Gage J, Leonard F, Srinivasan S, Souza GR, Dave B, Godin B (2014) Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation. Sci Rep 4:1–9. https://doi.org/10.1038/srep06468
Jawahar N, De A, Jubee S, Reddy ES (2020) Folic acid-conjugated raloxifene hydrochloride carbon nanotube for targeting breast cancer cells. Drug Dev Res 81(3):305–314. https://doi.org/10.1002/ddr.21620
Jia R, Li Z, Liang W, Ji Y, Weng Y, Liang Y, Ning P (2020) Identification of key genes unique to the luminal a and basal-like breast cancer subtypes via bioinformatic analysis. World J Surg Oncol 18(1):268. https://doi.org/10.1186/s12957-020-02042-z
Katt ME, Placone AL, Wong AD, Xu ZS, Searson PC (2016) In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol 4:12. https://doi.org/10.3389/fbioe.2016.00012
Kim Y, Park EJ, Na DH (2018) Recent progress in dendrimer-based nanomedicine development. Arch Pharmacal Res 41(6):571–582. https://doi.org/10.1007/s12272-018-1008-4
Klochkov SG, Neganova ME, Nikolenko VN, Chen K, Somasundaram SG, Kirkland CE, Aliev G (2021) Implications of nanotechnology for the treatment of cancer: recent advances. Semin Cancer Biol 69:190–199. https://doi.org/10.1016/j.semcancer.2019.08.028
Kolářová I, Vaňásek J, Odrážka K, Dušek L, Šinkorová Z, Hlávka A, Vilasová Z (2019) Is there a benefit of HER2-positive breast cancer subtype determination in clinical practice? Klinicka Onkologie 32(1):25–30. https://doi.org/10.1473/amko2019
Kumar M, Raza K (2017) C60-fullerenes as drug delivery carriers for anticancer agents: promises and hurdles. Pharm Nanotechnol 5(3):169–179. https://doi.org/10.2174/2211738505666170301142232
Kunte S, Abraham J, Montero AJ (2020) Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer 126(19):4278–4288. https://doi.org/10.1002/cncr.33102
Law S, Leung AW, Xu C (2020) Folic acid-modified celastrol nanoparticles: synthesis, characterization, anticancer activity in 2D and 3D breast cancer models. Artif Cells Nanomed Biotechnol 48(1):542–559. https://doi.org/10.1080/21691401.2020.1725025
Li D, Yao S, Zhou Z, Shi J, Huang Z, Wu Z (2020a) Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin. Carbohyd Res 493:108032. https://doi.org/10.1016/j.carres.2020.108032
Li S, Wu Y, Ding F, Yang J, Li J, Gao X, Feng J (2020b) Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale 12(19):10854–10862. https://doi.org/10.1039/d0nr00523a
Li Y, Qian D, Lin H-P, Xie J, Yang P, Maddy D, Yang C (2021) Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells. J Controlled Release 329:833–846. https://doi.org/10.1016/j.jconrel.2020.10.015
Madaan K, Kumar S, Poonia N, Lather V, Pandita D (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioall Sci 6(3):139–150. https://doi.org/10.4103/0975-7406.130965
Mahdi WA, Hussain A, Ramzan M (2020) 5-Fluorouracil loaded biogenic and albumin capped gold nanoparticles using bacterial enzyme—in vitro-in silico gastroplus® simulation and prediction. Processes 8(12):1–27. https://doi.org/10.3390/pr8121579
Mahdi WA, Hussain A, Ramzan M, Faruk A, Bukhari SI, Dev A (2021) Pluronic-coated biogenic gold nanoparticles for colon delivery of 5-fluorouracil: in vitro and ex vivo studies. AAPS PharmSciTech 22(2):64. https://doi.org/10.1208/s12249-021-01922-1
Mahor A, Singh PP, Bharadwaj P, Sharma N, Yadav S, Rosenholm JM, Bansal KK (2021) Carbon-based nanomaterials for delivery of biologicals and therapeutics: a cutting-edge technology. C 7(1):19. https://doi.org/10.3390/c7010019
Maiti D, Tong X, Mou X, Yang K (2019) Carbon-based nanomaterials for biomedical applications: a recent study. Front Pharmacol 9:1–16. https://doi.org/10.3389/fphar.2018.01401
Maja L, Željko K, Mateja P (2020) Sustainable technologies for liposome preparation. J Supercrit Fluids. https://doi.org/10.1016/j.supflu.2020.104984
Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, Yousefi B (2020) Overcoming multidrug resistance in cancer: recent progress in nanotechnology and new horizons. IUBMB Life 72(5):855–871. https://doi.org/10.1002/iub.2215
Malhotra MK, Emens LA (2020) The evolving management of metastatic triple negative breast cancer. Semin Oncol 47(4):229–237. https://doi.org/10.1053/j.seminoncol.2020.05.005
Mamnoon B, Feng L, Froberg J, Choi Y, Sathish V, Mallik S (2020) Hypoxia-responsive, polymeric nanocarriers for targeted drug delivery to estrogen receptor-positive breast cancer cell spheroids. Mol Pharm 17(11):4312–4322. https://doi.org/10.1021/acs.molpharmaceut.0c00754
Mangla B, Neupane YR, Singh A, Kumar P, Shafi S, Kohli K (2020) Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. Nanomedicine (lond) 15(26):2563–2583. https://doi.org/10.2217/nnm-2020-0277
Mao L, Li J, Chen W-X, Cai Y-Q, Yu D-D, Zhong S-L, Tang J-H (2016) Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol 37(4):5247–5256. https://doi.org/10.1007/s13277-015-4402-2
Matea CT, Mocan T, Tabaran F, Pop T, Mosteanu O, Puia C, Fodor O (2017) Quantum dots in imaging, drug delivery and sensor applications. Int J Nanomed. https://doi.org/10.2147/IJN.S138624
McKernan P, Virani NA, Faria GNF, Karch CG, Prada Silvy R, Resasco DE, Harrison RG (2021) Targeted single-walled carbon nanotubes for photothermal therapy combined with immune checkpoint inhibition for the treatment of metastatic breast cancer. Nanoscale Res Lett 16(1):9. https://doi.org/10.1186/s11671-020-03459-x
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery 20(2):101–124. https://doi.org/10.1038/s41573-020-0090-8
Mohammadpour Z, Majidzadeh-A K (2020) Applications of two-dimensional nanomaterials in breast cancer theranostics. ACS Biomater Sci Eng 6(4):1852–1873. https://doi.org/10.1021/acsbiomaterials.9b01894
Moradi-Chaleshtori M, Bandehpour M, Heidari N, Mohammadi-Yeganeh S, Mahmoud Hashemi S (2021) Exosome-mediated miR-33 transfer induces M1 polarization in mouse macrophages and exerts antitumor effect in 4T1 breast cancer cell line. Int Immunopharmacol 90:107198. https://doi.org/10.1016/j.intimp.2020.107198
Moraes S, Marinho A, Lima S, Granja A, Araújo JP, Reis S, Nunes C (2021) Targeted nanostructured lipid carriers for doxorubicin oral delivery. Int J Pharm 592:120029. https://doi.org/10.1016/j.ijpharm.2020.120029
Mu Q, Wang H, Zhang M (2017) Nanoparticles for imaging and treatment of metastatic breast cancer. Physiol Behav 176(5):139–148. https://doi.org/10.1016/j.physbeh.2017.03.040
Muthu MS, Wilson B (2012) Challenges posed by the scale-up of nanomedicines. Nanomedicine 7(3):307–309. https://doi.org/10.2217/nnm.12.3
Nagayama A, Vidula N, Ellisen L, Bardia A (2020) Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol 12:1758835920915980. https://doi.org/10.1177/1758835920915980
Norouzi P, Amini M, Dinarvand R, Arefian E, Seyedjafari E, Atyabi F (2020) Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers. Mater Sci Eng 116:111161. https://doi.org/10.1016/j.msec.2020.111161
Nunnery SE, Mayer IA, Balko JM (2021) Triple-negative breast cancer: breast tumors with an identity crisis. Cancer J 27(1):2–7. https://doi.org/10.1097/PPO.0000000000000494
Paliwal R, Babu RJ, Palakurthi S (2014) Nanomedicine scale-up technologies: feasibilities and challenges. Ageing Int 15(6):1527–1534. https://doi.org/10.1208/s12249-014-0177-9
Paliwal S, Pandey K, Pawar S, Joshi H, Bisht N (2020) A review on carbon nanotubes: as a nano carrier drug delivery system. Indian J Pharm Sci 82(5):766–772. https://doi.org/10.36468/pharmaceutical-sciences.704
Patel D, Patel B, Thakkar H (2021) Lipid based nanocarriers: promising drug delivery system for topical application. Eur J Lipid Sci Technol 123(5):2000264. https://doi.org/10.1002/ejlt.202000264
Pindiprolu SKSS, Krishnamurthy PT, Chintamaneni PK, Karri VVSR (2018) Nanocarrier based approaches for targeting breast cancer stem cells. Artif Cells Nanomed Biotechnol 46(5):885–898. https://doi.org/10.1080/21691401.2017.1366337
Pindiprolu SKSS, Krishnamurthy PT, Ghanta VR, Chintamaneni PK (2020) Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer. Nanomedicine 15(16):1551–1565. https://doi.org/10.2217/nnm-2020-0003
Pindiprolu SKSS, Krishnamurthy PT, Dev C, Chintamaneni PK (2021) DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Chem Phys Lipid 235:105033. https://doi.org/10.1016/j.chemphyslip.2020.105033
Priestnall SL, Okumbe N, Orengo L, Okoth R, Gupta S, Gupta NN, Chatterjee R (2020) No title. Endocrine 9:6
Rai N, Madni A, Faisal A, Jamshaid T, Khan MI, Khan MM, Parveen F (2021) Glyceryl monostearate based solid lipid nanoparticles for controlled delivery of docetaxel. Curr Drug Deliv. https://doi.org/10.2174/1567201818666210203180153
Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, Kumar D (2021) Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol 69:166–177. https://doi.org/10.1016/j.semcancer.2019.11.002
Ranjbar-Navazi Z, Fathi M, Abdolahinia ED, Omidi Y, Davaran S (2021) MUC-1 aptamer conjugated InP/ZnS quantum dots/nanohydrogel fluorescent composite for mitochondria-mediated apoptosis in MCF-7 cells. Mater Sci Eng 118:111469. https://doi.org/10.1016/j.msec.2020.111469
Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, Pandit JK (2014) Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Deliv 2014:670815. https://doi.org/10.1155/2014/670815
Rehan F, Ahemad N, Islam RA, Gupta M, Gan SH, Chowdhury EH (2020) Optimization and formulation of nanostructured and self-assembled caseinate micelles for enhanced cytotoxic effects of paclitaxel on breast cancer cells. Pharmaceutics. https://doi.org/10.3390/pharmaceutics12100984
Reshma VG, Mohanan PV (2019) Quantum dots: applications and safety consequences. J Lumin 205:287–298. https://doi.org/10.1016/j.jlumin.2018.09.015
Rolle F, Bincoletto V, Gazzano E, Rolando B, Lollo G, Stella B, Arpicco S (2020) Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. Int J Pharm 580:119191. https://doi.org/10.1016/j.ijpharm.2020.119191
Rugo HS (2021) Update on antibody-drug conjugates in breast cancer. Clin Adv Hematol Oncol 19(3):148–151
Samimi S, Ardestani MS, Dorkoosh FA (2021) Preparation of carbon quantum dots- quinic acid for drug delivery of gemcitabine to breast cancer cells. J Drug Deliv Sci Technol 61:102287. https://doi.org/10.1016/j.jddst.2020.102287
Shaikh SS, Emens LA (2020) Current and emerging biologic therapies for triple negative breast cancer. Expert Opin Biol Ther. https://doi.org/10.1080/14712598.2020.1801627
Sharmiladevi P, Girigoswami K, Haribabu V, Girigoswami A (2021) Nano-enabled theranostics for cancer. Mater Adv. https://doi.org/10.1039/d1ma00069a
Shirodkar RK, Kumar L, Mutalik S, Lewis S (2019) Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems. Pharm Chem J 53(5):440–453. https://doi.org/10.1007/s11094-019-02017-9
Shojaei S, Hashemi SM, Ghanbarian H, Sharifi K, Salehi M, Mohammadi-Yeganeh S (2021) Delivery of miR-381-3p mimic by mesenchymal stem cell-derived exosomes inhibits triple negative breast cancer aggressiveness; an in vitro study. Stem Cell Rev Rep. https://doi.org/10.1007/s12015-020-10089-4
Shrestha B, Wang L, Zhang H, Hung CY, Tang L (2020) Gold nanoparticles mediated drug-gene combinational therapy for breast cancer treatment. Int J Nanomed 15:8109–8119. https://doi.org/10.2147/IJN.S258625
Singh SK, Singh S, Lillard JW Jr, Singh R (2017) Drug delivery approaches for breast cancer. Int J Nanomed 12:6205–6218
Singh MK, Pindiprolu SKSS, Sanapalli BKR, Yele V, Ganesh GNK (2020) HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer. Int J Biol Macromol 150:631–636. https://doi.org/10.1016/j.ijbiomac.2020.02.131
Sohail M, Guo W, Li Z, Xu H, Zhao F, Fu F, Chen D (2020) Nanocarrier-based drug delivery system for cancer therapeutics: a review of the last decade. Curr Med Chem 27:1–19. https://doi.org/10.2174/0929867327666201005111722
Soni NK, Sonali LJ, Singh A, Mangla B, Neupane YR, Kohli K (2020) Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology 31(47):475101. https://doi.org/10.1088/1361-6528/abaf81
Sorolla A, Sorolla MA, Wang E, Ceña V (2020) Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment. Expert Opin Drug Deliv 17(11):1597–1613. https://doi.org/10.1080/17425247.2020.1814733
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. https://doi.org/10.3322/caac.21660
Swain S, Sahu P, Beg S, Babu S (2016) Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv. https://doi.org/10.2174/1567201813666160713121122
Tajau R, Rohani R, Abdul Hamid SS, Adam Z, Mohd Janib SN, Salleh MZ (2020) Surface functionalisation of poly-APO-b-polyol ester cross-linked copolymers as core-shell nanoparticles for targeted breast cancer therapy. Sci Rep 10(1):21704. https://doi.org/10.1038/s41598-020-78601-x
Teles RHG, Moralles HF, Cominetti MR (2018) Global trends in nanomedicine research on triple negative breast cancer: a bibliometric analysis. Int J Nanomed 13:2321–2336. https://doi.org/10.2147/IJN.S164355
Toosi K (2014) NIH public access. Bone 23(1):1–7. https://doi.org/10.1016/j.ijrobp.2013.02.009.Preclinical
Tran S, DeGiovanni P-J, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. https://doi.org/10.1186/s40169-017-0175-0
Umapathi A, Kumawat M, Daima HK (2021) Engineered nanomaterials for biomedical applications and their toxicity: a review. Environ Chem Lett. https://doi.org/10.1007/s10311-021-01307-7
Venkatesh N (2018) Metallic nanoparticle: a review. Biomed J Sci Tech Res 4(2):3765–3775. https://doi.org/10.2671/bjstr.2018.04.0001011
Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. P T 42(12):742–755
Verma NK, Roshan A (2015) Liposomes: a targeted drug delivery system—a review review article liposomes: a targeted drug delivery system—a review. Acta Medica Scientia 2(3):65–70
Vervald AM, Burikov SA, Scherbakov AM, Kudryavtsev OS, Kalyagina NA, Vlasov II, Dolenko TA (2020) Boron-doped nanodiamonds as anticancer agents: en route to hyperthermia/thermoablation therapy. ACS Biomater Sci Eng 6(8):4446–4453. https://doi.org/10.1021/acsbiomaterials.0c00505
Wang F, Su Q, Umar K, Nasir M, Ibrahim M, Yaqoob AA, Qari HA (2020) Article 341 and Mohamad Ibrahim MN (2020) Recent advances in metal decorated nanomaterials and their various biological applications: a. Rev Front Chem 8:341. https://doi.org/10.3389/fchem.2020.00341
Wang P, Yan G, Zhu X, Du Y, Chen D, Zhang J (2021) Heterofullerene mc59 (M = b, si, al) as potential carriers for hydroxyurea drug delivery. Nanomaterials 11(1):1–10. https://doi.org/10.3390/nano11010115
Weigelt B, Geyer FC, Reis-Filho JS (2010) Histological types of breast cancer: how special are they? Mol Oncol 4(3):192–208. https://doi.org/10.1016/j.molonc.2010.04.004
White BE, White MK, Adhvaryu H, Makhoul I, Nima ZA, Biris AS, Ali N (2020) Nanotechnology approaches to addressing HER2-positive breast cancer. Cancer Nanotechnol 11(1):1–26. https://doi.org/10.1186/s12645-020-00068-2
Wu Di, Si M, Xue HY, Wong HL (2017) Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomed 12:5879–5892. https://doi.org/10.2147/IJN.S123437
Wu D, Zhao Z, Kim J, Razmi A, Wang LL-W, Kapate N, Mitragotri S (2021) Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer. Bioeng Transl Med 6(1):e10188. https://doi.org/10.1002/btm2.10188
Yaghoubi S, Gharibi T, Karimi MH, Sadeqi Nezhad M, Seifalian A, Tavakkol R, Abdollahpour-Alitappeh M (2021) Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Breast Cancer (tokyo, Japan) 28(1):216–225. https://doi.org/10.1007/s12282-020-01153-5
Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):1–13. https://doi.org/10.1186/s13058-020-01296-5
Zavareh HS, Pourmadadi M, Moradi A, Yazdian F, Omidi M (2020) Chitosan/carbon quantum dot/aptamer complex as a potential anticancer drug delivery system towards the release of 5-fluorouracil. Int J Biol Macromol 165:1422–1430. https://doi.org/10.1016/j.ijbiomac.2020.09.166
Zhang Y, Huang Y, Li S (2014) Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 15(4):862–871. https://doi.org/10.1208/s12249-014-0113-z
Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y (2020) Recent advances of antibody drug conjugates for clinical applications. Acta Pharmaceutica Sinica B 10(9):1589–1600. https://doi.org/10.1016/j.apsb.2020.04.012
Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Brugge JS (2020) Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res 22(1):132. https://doi.org/10.1186/s13058-020-01374-8
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
All authors contributed in conceptualizing and designing of the manuscript. PB, LG and GS contributed in writing the manuscript. DG, NK and RS contributed the advanced nanomedicine section in the manuscript. AS and GS conceptualized and analysed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
There are no actual or potential conflicts of interest.
Rights and permissions
About this article
Cite this article
Banthia, P., Gambhir, L., Sharma, A. et al. Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer. 3 Biotech 12, 70 (2022). https://doi.org/10.1007/s13205-022-03121-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-022-03121-6